Outcomes According to ALK Status Determined by Central Immunohistochemistry or Fluorescence In Situ Hybridization in Patients With ALK-Positive NSCLC Enrolled in the Phase 3 ALEX Study.
暂无分享,去创建一个
A. Shaw | S. Ou | T. Mok | S. Peters | D. Camidge | Dong-Wan Kim | S. Gadgeel | E. Pozzi | Ting Liu | J. Noé | K. Konopa | I. Loftin | Crystal Williams | C. Williams